Güren, A.K.; Guliyev, M.; Alan, Ö.; Çadırci, K.; Belevi, İ.N.; Gültürk, İ.; Özge, E.; Kocaaslan, E.; Ağyol, Y.; Erel, P.;
et al. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors. J. Clin. Med. 2025, 14, 1071.
https://doi.org/10.3390/jcm14041071
AMA Style
Güren AK, Guliyev M, Alan Ö, Çadırci K, Belevi İN, Gültürk İ, Özge E, Kocaaslan E, Ağyol Y, Erel P,
et al. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors. Journal of Clinical Medicine. 2025; 14(4):1071.
https://doi.org/10.3390/jcm14041071
Chicago/Turabian Style
Güren, Ali Kaan, Murad Guliyev, Özkan Alan, Kıvanç Çadırci, İpek Naz Belevi, İlkay Gültürk, Emre Özge, Erkam Kocaaslan, Yeşim Ağyol, Pınar Erel,
and et al. 2025. "Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors" Journal of Clinical Medicine 14, no. 4: 1071.
https://doi.org/10.3390/jcm14041071
APA Style
Güren, A. K., Guliyev, M., Alan, Ö., Çadırci, K., Belevi, İ. N., Gültürk, İ., Özge, E., Kocaaslan, E., Ağyol, Y., Erel, P., Paçacı, B., Tunç, M. A., Majidova, N., Sever, N., Çelebi, A., Arıkan Erdoğan, R., Işık, S., Demirci, N. S., Sarı, M.,
... Bayoğlu, İ. V.
(2025). Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors. Journal of Clinical Medicine, 14(4), 1071.
https://doi.org/10.3390/jcm14041071
